Related Experiment Video

Updated: Dec 15, 2025

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

16.3K

Nonconsensual Dose Reduction Mandates are Not Justified Clinically or Ethically: An Analysis.

Stefan G Kertesz1, Ajay Manhapra1, Adam J Gordon1

  • 1Stefan G. Kertesz, M.D., M.Sc., is a professor at the Department of Medicine, UAB School of Medicine and research investigator at the Birmingham VA Medical Center. He is a board-certified internal medicine (American Board of Internal Medicine) and addiction medicine physician (American Board of Addiction Medicine). His research career began in 2000 and he has been funded by both the National Institute on Drug Abuse and the Health Services Research & Development Branch of the Department of Veterans Affairs. He received his MD from Harvard Medical School in Boston, MA and his MSc from Boston University School of Public Health in Boston, MA. Ajay Manhapra, M.D., is Lecturer at Yale School of Medicine in the Department of Psychiatry, Assistant Professor, at the Eastern Virginia Medical School in the Department of Physical Medicine and Rehabilitation and Psychiatry, and Research Scientist at the VA New England Mental Illness Research, Education and Clinical Center. Dr. Manhapra is a board-certified Internist and Addiction Medicine physician with educational, clinical and research focus on pain and addiction. He runs a unique clinic for recovering patients with severe disabling chronic pain and medication or substance dependence at Hampton VA Medical Center, where he is developing an interdisciplinary integrative model for treatment of pain and addiction. Dr. Manhapra received his medical degree from Government Medical College, Thrissur, Kerala, India, and completed his Addiction Medicine fellowship at Yale School of Medicine. Adam J. Gordon, M.D., M.P.H., is Professor of Medicine and Psychiatry at the University of Utah School of Medicine, Director of the Program for Addiction Research, Clinical Care, Knowledge, and Advocacy (PARCKA), and Chief of Addiction Medicine at VA Salt Lake City Health Care System and. He is a board-certified internal medicine (American Board of Internal Medicine) and addiction medicine physician (American Board of Preventive Medicine) with a 20-year track record of conducting research on the quality, equity, and efficiency of health care for vulnerable populations (e.g., persons with opioid use disorders, persons who are homeless, persons with hazardous alcohol use and other addiction disorders). He received his MD from University of Pittsburgh School of Medicine in Pittsburgh, PA and his MPH from the University of Pittsburgh Graduate School of Public Health in Pittsburgh, PA.

The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|July 8, 2020
PubMed
Summary

Mandating opioid dose reduction for long-term patients lacks clinical evidence and safety justification. Healthcare providers face pressure, but policy incentives for forced reduction are not supported by guidelines or data.

More Related Videos

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

47.3K
X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging08:30

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging

Published on: September 11, 2011

14.7K

Related Concept Videos

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
126
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.1K
Ethical Dilemmas I01:17

Ethical Dilemmas I

Ethical dilemmas in nursing are of utmost importance, as they often arise from the tension between adhering to core ethical principles and the practical realities of healthcare delivery. These dilemmas require nurses to navigate complex situations where competing ethical considerations pull them in different directions.
Let us explore some examples to understand the potentially complex moral decisions nurses face.
Take the case of caring for minors, particularly in areas related to reproductive...
1.6K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
103
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
145
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
176